JP Morgan Chase
VTGN icon

JP Morgan Chase’s VistaGen Therapeutics VTGN Stock Holding History

JP Morgan Chase’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62 Buy
82
+66
+413% +$40 ﹤0.01% 7573
2026
Q1 		$9 Hold
16
– – ﹤0.01% 7440
2025
Q4 		$11 Sell
16
-271,809
-100% -$982K ﹤0.01% 7330
2025
Q3 		$965K Sell
271,825
-477,037
-64% -$1.43M ﹤0.01% 4625
2025
Q2 		$1.5M Sell
748,862
-2,014
-0.3% -$4.58K ﹤0.01% 4121
2025
Q1 		$1.88M Sell
750,876
-21,368
-3% -$60.5K ﹤0.01% 3924
2024
Q4 		$2.28M Buy
772,244
+772,228
+4,826,425% +$2.17M ﹤0.01% 4050
2024
Q3 		$48 Hold
16
– – ﹤0.01% 7128
2024
Q2 		$56 Hold
16
– – ﹤0.01% 7008
2024
Q1 		$84 Hold
16
– – ﹤0.01% 6939
2023
Q4 		$82 Hold
16
– – ﹤0.01% 7143
2023
Q3 		$84 Sell
16
-465
-97% -$2.06K ﹤0.01% 6931
2023
Q2 		$899 Sell
481
-4,819
-91% -$16.9K ﹤0.01% 6470
2023
Q1 		$20K Buy
5,300
+1,610
+44% +$8.44K ﹤0.01% 5978
2022
Q4 		$11K Buy
3,690
+63
+2% +$237 ﹤0.01% 6014
2022
Q3 		$17K Buy
3,627
+152
+4% +$1.51K ﹤0.01% 5854
2022
Q2 		$92K Buy
3,475
+437
+14% +$15.4K ﹤0.01% 5456
2022
Q1 		$113K Buy
3,038
+535
+21% +$23.3K ﹤0.01% 5451
2021
Q4 		$147K Sell
2,503
-4,008
-62% -$261K ﹤0.01% 5510
2021
Q3 		$536K Sell
6,511
-430
-6% -$37.4K ﹤0.01% 4677
2021
Q2 		$656K Buy
+6,941
New +$514K ﹤0.01% 4532

Other funds holding VTGN

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CWS
Confluence Wealth Services Mcmurray, Pennsylvania $3.5B AUM 22.08% 1-Year Est. Return

JP Morgan Chase's VTGN Position: Q2 2026 in Review

JP Morgan Chase increased its VistaGen Therapeutics (VTGN) stake by 413% in Q2 2026, buying an estimated $40 and bringing the position to 82 shares worth $62. The position accounts for ﹤0.01% of the portfolio, ranked #7573.

JP Morgan Chase first reported a position in VTGN in Q2 2021 and has held it in 21 quarters since. The position peaked at $2.28M in Q4 2024. 26 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • JP Morgan Chase held 82 shares of VistaGen Therapeutics worth $62 as of Q2 2026.
  • JP Morgan Chase bought 66 VistaGen Therapeutics shares in Q2 2026, an estimated $40.
  • VistaGen Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7573 holding.
  • JP Morgan Chase first reported a position in VistaGen Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • JP Morgan Chase's VistaGen Therapeutics position peaked at $2.28M in Q4 2024.
  • 26 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.